PRME Prime Medicine, Inc.
USHealthcareAs of 2026-07-10 16:00
Why PRME matters now
Prime Medicine, Inc. (PRME) is a US stock in Healthcare. The latest InvestLog snapshot shows $3.78 with -10.64% on the session and $682.7M in market capitalization; recent performance reads 1-month +19.63% and YTD -6.92%.
The latest financial table shown here is Q1 2026, with revenue of $856.0K, net income of $-49.1M, and EPS of $-0.28. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -27.2%.
The latest indexable market news headline is "Prime Medicine Beats Beam Therapeutics In Patent Dispute - But Both Are Investable" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Buy with a median target of $17.00; recent insider activity includes Cahill Thomas filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
7.46
P/S
144.62
EV/EBITDA
-3.32
DCF Value
$-0.06
FCF Yield
-27.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
-1082.7%
Operating Margin
-5121.8%
Net Margin
-4917.6%
ROE
-188.8%
ROA
-67.3%
ROIC
-77.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $856.0K | $-49.1M | $-0.28 |
| Q4 2025 | $838.0K | $-46.1M | $-0.26 |
| FY 2025 | $4.6M | $-201.1M | $-1.35 |
| Q3 2025 | $1.2M | $-50.6M | $-0.32 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$17.25
Target (Median)
$17.00
Target Range
$12.00 - $23.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
2.31
Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence. The company, founded in 2019, maintains its headquarters in Cambridge, Massachusetts.